Skip to content

The effect of Emdogain on changes in cytokine profile during early wound healing

Enamel matrix derivatives in periodontal regenerative surgery modulates cytokine profiles: A randomised controlled clinical trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN13262303
Enrollment
15
Registered
2016-02-22
Start date
2014-01-01
Completion date
Unknown
Last updated
2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Generalized severe chronic periodontitis Oral Health Generalized severe chronic periodontitis

Interventions

All participants present two teeth in different regions of the mouth that require surgical treatment. One of these teeth is randomly selected to undergo open flap debridement with the application of E

Sponsors

Regional Committees for Medical and Health Research Ethics (REK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged between 25 and 75 years 2. Non-smoking 3. No use of antibiotics over the previous 6 months prior to treatment 4. The presence of one pair of interproximal sites with probing pocket depth (PPD) of 6 mm or more, horizontal and/or vertical bone loss as demonstrated by the probing measurement and radiographic assessments following the initial phase of periodontal treatment 5. Experimental teeth must either have a vital pulp or, if subjected to root canal treatment, be asymptomatic, and without technical remarks 6. Prior to the start of the trial, the patients will give informed consent

Exclusion criteria

Exclusion criteria: 1. Patients with a systemic condition like diabetes mellitus, cancer, HIV, disorders that compromise wound healing, chronic high dose steroid therapy, bone metabolic disease, radiation or immune-suppressive therapy 2. Patients with acute infectious lesions in the area of intended therapy

Design outcomes

Primary

MeasureTime frame
Cytokine levels in gingival fluid are measured using the Luminex-200 system (multiplex bead-based immunoassay) at baseline, 7 and 14 days postoperatively.

Countries

Norway

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026